Archives
-
HyperScribe™ Poly (A) Tailing Kit: Evidence Overview
2026-10-04
A source-grounded overview of the HyperScribe™ Poly (A) Tailing Kit, examining its enzymatic rationale, conceptual research applications, evidence provenance, and limitations without presenting experimental procedures.
-
ECE-1c Stability and Silmitasertib in Lung Cancer
2026-10-01
Almarza and colleagues identify ECE-1c stability as a mechanistic link between CK2 activity, cancer stem cell-like traits, cisplatin resistance, and invasive behavior in non-small cell lung cancer models. Their Lys-6 mutation strategy and pharmacologic CK2 perturbation support ECE-1c as a candidate biomarker and Silmitasertib as a tool for testing this pathway, while leaving clinical efficacy and patient-level relevance to future studies.
-
H-89 for PKA and cAMP Signaling Studies
2026-10-01
H-89 provides an acute pharmacological way to test whether PKA contributes to cAMP-linked signaling, Wnt-driven osteoblast metabolism, proliferation, or apoptosis. Its greatest value comes from pairing concentration-response experiments with pathway-specific readouts, viability controls, and orthogonal validation rather than treating a single cellular dose as proof of PKA selectivity.
-
Berberrubine and NAFLD: Metabolic and Microbiota Insights
2026-09-30
The reference study identifies berberrubine, a major berberine metabolite, as an active mediator of improved hepatic steatosis and insulin resistance in high-fat diet mice and oleic acid-treated HepG2 cells. Its integrated analysis of metabolic proteins and gut microbiota provides a useful framework for distinguishing metabolite-specific activity from the effects of the parent compound.
-
Modified Ethanol-Injected mRNA Lipoplexes as Tumour Vaccines
2026-09-30
The 2024 Journal of Drug Targeting study optimized PEGylation of cationic mRNA lipoplexes made by a modified ethanol injection method. A 3 mol% PEG-Chol formulation reduced erythrocyte agglutination and lung accumulation while supporting strong anti-OVA antibody responses, cytotoxic activity, and tumour-growth suppression after intravenous vaccination in mice.
-
Cholesterol (B1702) for Reliable Cell Assays
2026-09-29
Learn how Cholesterol, SKU B1702, can improve the interpretability of membrane, viability, proliferation, and lipid metabolism experiments through controlled formulation and storage practices. This scenario-based guide connects practical assay design with evidence from localized mRNA–LNP research while distinguishing established product specifications from workflow recommendations.
-
(R)-MG132: A Rigorous Proteasome Negative Control
2026-09-29
Learn how (R)-MG132 (SKU C3348) strengthens proteasome inhibition validation in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide covers assay design, handling, interpretation, vendor selection, and connections to current cancer-metabolism research.
-
Isoprenaline Hydrochloride: Research Workflows
2026-09-28
Isoprenaline Hydrochloride, also known as isoproterenol, provides a controllable way to model β-adrenergic stimulation across cardiac, neurobehavioral, airway, and endothelial assays. This guide translates recent heart–brain research into practical workflows, assay controls, and troubleshooting strategies.
-
Triiodothyronine (T3) and Precision Cell Models
2026-09-28
A translational framework for studying Triiodothyronine (T3) alongside precision gene editing—without conflating thyroid hormone signaling with the mechanisms of base editing.
-
L-Phenylephrine for Baroreflex Assay Design
2026-09-27
L-Phenylephrine is an adrenergic α1A receptor agonist that can help researchers probe vascular and reflex components of cardiovascular regulation. This article interprets its role as a baroreflex challenge in angiotensin II hypertension research, with emphasis on sex as an experimental variable and on limits of mechanistic inference.
-
Phosbind Acrylamide for FDXR Phosphorylation Analysis
2026-09-26
Phosbind Acrylamide turns protein phosphorylation into a gel-mobility readout, helping researchers compare phosphorylated and non-phosphorylated forms without relying on phospho-specific antibodies. Applied to FDXR, it can support stress-response and AKT-signaling experiments—but a mobility shift is a screening result, not proof of a specific phosphorylation site.
-
Viral RIPK3 Degradation Shapes Infection-Driven Inflammation
2026-09-25
Liu and colleagues identified a family of orthopoxvirus proteins that recruits host ubiquitin machinery to degrade RIPK3, suppressing necroptosis. Viral-genetic and mouse experiments show that this pathway can increase viral replication while also shaping inflammation and disease severity, linking viral immune evasion to host cell-death signaling.
-
Tunable Human Intestinal Organoids Balance Cell Fates
2026-09-25
Yang and colleagues describe a human small intestinal organoid system that combines strong stem-cell self-renewal with broader epithelial differentiation under a single culture condition. By enhancing stemness and then tuning cell-fate signals, the study offers a route to more diverse, proliferative organoids without imposing artificial spatial gradients.
-
HRP Rabbit Anti-Goat IgG (H+L) Antibody for p21
2026-09-24
Turn p21 mRNA–LNP experiments into interpretable protein-level evidence with a sensitive secondary antibody for goat primary antibodies. This workflow connects bladder-tumor biology to practical western blot, ELISA, and tissue-staining readouts while keeping assay-specific limits clear.
-
Berbamine hydrochloride in Cancer Research
2026-09-24
Use Berbamine hydrochloride to probe cancer-cell signaling and test how pathway perturbation relates to ferroptosis-associated phenotypes—without assuming it targets the METTL16–SENP3–LTF axis. This practical guide combines reported cell-line potency with a cautious, control-rich workflow for KU812 and HepG2 experiments.